On October 26th, according to Eli Lilly, the Medicines and Medical Products Regulatory Authority (MHRA) in the UK has granted marketing authorization for its drug donanemab. Donanemab (trade name: Kisunla) is a medication used for intravenous infusion, administered once every four weeks, approved in the UK for the treatment of eligible adult patients with mild cognitive impairment and mild Alzheimer's disease (AD). Previously, donanemab had obtained marketing authorization in the United States, United Arab Emirates, Japan, and Qatar. In China, donanemab has been granted breakthrough therapeutic drug certification and included in the priority review and approval process by the China National Medical Products Administration, and is currently undergoing the review and approval process.